Anti-ROR1 Antibody (Zilovertamab): Enabling Precision in Liver Injury and Cancer Assays

Principle Overview: Targeting ROR1 for Mechanistic Clarity

The Anti-ROR1 Antibody (Zilovertamab) stands as a humanized monoclonal antibody engineered to selectively inhibit receptor tyrosine kinase-like orphan receptor 1 (ROR1)—a transmembrane protein activated by Wnt5a and implicated in tumor progression, metastasis, and, as emerging evidence suggests, liver injury models. By blocking Wnt5a-induced ROR1 signaling, Zilovertamab not only suppresses oncogenic pathways but also provides a mechanistically rigorous tool for dissecting the crosstalk between mitophagy, cell death, and inflammatory cascades in complex disease models.

Produced in CHO cells and purified to >95% homogeneity via Protein A chromatography (product information), the antibody’s unconjugated IgG1 format and stringent buffer formulation ensure high specificity and minimal background, critical for quantitative applications such as ELISA and FACS. Its proven ability to bind immobilized human ROR1 at 2 µg/mL underscores its functional reliability, making it ideal for both in vitro and in vivo workflows.

Step-by-Step Workflow Enhancements

The versatility of Zilovertamab is best realized in carefully optimized experimental pipelines. Below, we outline a streamlined workflow tailored to researchers modeling Wnt5a-induced ROR1 signaling in cancer or toxicology contexts:

1. Reconstitution and Handling: Upon receipt, the antibody (supplied as a liquid in 100 mM proline and 20 mM arginine, pH 5.0, without preservatives) should be aliquoted and stored at -80°C to avoid freeze-thaw cycles. For reconstitution, add sterile distilled water to reach the desired concentration, mixing gently to prevent protein denaturation.
2. ELISA and FACS Setups: For ELISA, coat plates with ROR1-expressing lysates or recombinant protein, block with 1% BSA, and apply Zilovertamab at 2 µg/mL for primary incubation. In FACS, stain cells with the antibody at 1–5 µg/mL, followed by species-matched secondary detection if needed, ensuring minimal background and robust signal.
3. Functional Inhibition Assays: To interrogate Wnt5a-induced ROR1 signaling, pre-incubate target cells with 2–10 µg/mL Zilovertamab for 30–60 minutes prior to Wnt5a stimulation. Assess downstream markers of pathway activation, cell viability, or apoptosis by flow cytometry or immunoblotting.
4. Animal Model Integration: For in vivo studies (e.g., xenograft or toxin-induced liver injury), administer Zilovertamab via intraperitoneal injection at 5–20 mg/kg, referencing published regimens that balance efficacy and tolerability (see application in liver injury models).

Protocol Parameters

• ELISA primary antibody incubation: 2 µg/mL Anti-ROR1 Antibody (Zilovertamab), 1 hour at room temperature.
• FACS staining: 5 µg/mL antibody per 1×10⁶ cells, 30 minutes on ice, wash thoroughly with PBS + 1% BSA.
• Functional inhibition (in vitro): Pre-treat cells with 10 µg/mL Zilovertamab for 45 minutes before Wnt5a stimulation (100 ng/mL, 30 minutes).
• In vivo dosing (mouse model): 10 mg/kg intraperitoneally, once every 3 days for a 2-week course.

Key Innovation from the Reference Study

The recent study by Wangyong Yu et al. marks a pivotal advance in our understanding of liver injury mechanisms, revealing that deoxynivalenol (DON) exposure triggers liver damage by overactivating PINK1/Parkin-mediated mitophagy and simultaneously suppressing the cytoprotective p62-Keap1-Nrf2 pathway. This dual-hit mechanism leads to mitochondrial dysfunction, oxidative stress, and impaired hepatic resilience. For researchers, these insights provide a robust rationale for modeling both mitophagic flux and cytoprotective signaling within the same experimental system, and for probing how targeted interventions—such as Wnt5a-ROR1 axis inhibition—may modulate these outcomes.

Practically, deploying Anti-ROR1 Antibody (Zilovertamab) in such models allows for precise dissection of Wnt5a-induced ROR1’s role in promoting or mitigating mitophagy-driven injury, facilitating the development of more nuanced liver injury assays that reflect disease complexity. This approach complements the use of mitophagy inhibitors or genetic tools (e.g., si-PINK1) and invites comparative analysis across intervention strategies.

Advanced Applications and Comparative Advantages

What sets Zilovertamab apart is its ability to bridge mechanistic research in oncology and toxicology. In cancer research, its high specificity for ROR1 enables precise targeting of tumor cells, supporting functional assays that dissect the impact of Wnt5a-induced ROR1 signaling on proliferation, invasion, and drug sensitivity. This was highlighted in "Optimizing Cancer Assays with Anti-ROR1 Antibody (Zilovertamab)", where the antibody improved reproducibility and interpretability in cell viability and cytotoxicity workflows.

In the context of toxin-induced liver injury, as demonstrated by recent studies, Zilovertamab supports refined assay design by enabling direct interrogation of Wnt5a-ROR1 involvement in hepatocyte stress responses, apoptosis, and mitochondrial quality control. This dual-domain applicability is rarely matched by commercially available antibodies, making APExBIO’s offering a preferred choice for cross-disciplinary teams.

Moreover, the antibody’s unconjugated, high-purity format ensures compatibility with a broad range of secondary detection systems, enhancing both single- and multiplex readouts. Its stability profile—maintained at -80°C and resistant to aggregation when handled per guidelines—further reduces experimental variability, a critical consideration for longitudinal or high-throughput studies.

For translational efforts, as described in "Translational Insights and Assay Precision", Zilovertamab’s validated binding and functional inhibition data provide a robust foundation for protocol transfer between basic, preclinical, and applied settings.

Troubleshooting and Optimization Tips

• Low Signal in ELISA or FACS: Confirm antibody storage at -80°C, avoiding repeated freeze-thaw cycles; verify reconstitution with gentle inversion (never vortex).
• Non-specific Binding: Increase blocking buffer concentration (e.g., 5% BSA) or add a secondary antibody pre-adsorption step. Titrate primary antibody from 1–5 µg/mL to identify optimal concentration.
• Variable Functional Inhibition: Pre-screen Wnt5a stimulation doses to ensure pathway activation; for subtle phenotypes, extend Zilovertamab pre-incubation up to 2 hours and monitor downstream markers by immunoblot or flow cytometry.
• Batch-to-Batch Consistency: Leverage APExBIO’s batch certification data and, where possible, validate new lots in a side-by-side pilot before scale-up.
• Animal Model Variability: Standardize injection schedules, body weight normalization, and sample collection timing to ensure reproducibility in in vivo studies.

Future Outlook: Integrating Mechanistic and Translational Insights

The synergy between mechanistic studies—such as those elucidating DON-induced mitophagy and cytoprotective pathway suppression—and advanced antibody tools like Zilovertamab is poised to accelerate the refinement of both cancer and toxicology models. As the reference study underscores, granular interrogation of pathway-specific interventions will be essential for developing next-generation assays that capture the complexity of disease progression and response to therapy.

Looking forward, greater integration of Zilovertamab into multiplexed assay platforms, single-cell analyses, and sophisticated animal models promises to deepen our mechanistic understanding and drive translational progress in both oncology and environmental toxicology. APExBIO’s commitment to reagent quality and batch transparency ensures that researchers are equipped with reliable tools as these frontiers evolve.